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Summary
Background Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-
mediated complications in patients given allogeneic haemopoietic stem-cell transplantation (HSCT) from an 
unrelated donor, the optimum dose of this drug in children is still undefined. We aimed to test whether a higher dose 
of ATLG was superior to a lower dose for prevention of grade II–IV acute graft-versus-host disease (GVHD).
Methods We conducted a multicentre, randomised, open-label, phase 3 trial in seven Italian centres comparing 
two different doses of ATLG (30 mg/kg vs 15 mg/kg, given intravenously over 3 days, from day –4 to –2) in children 
(aged 0–18 years) with haematological malignancies transplanted from an unrelated donor, selected using high-resolution 
typing for HLA-class I/II loci. All patients received a myeloablative regimen and cyclosporine-A plus short-term 
methotrexate as post-transplantation GVHD prophylaxis. Patients were randomly assigned (1:1) to either of the two groups 
and were stratified by the degree of HLA-compatibility with their donor, the source of haemopoietic stem cells used (bone 
marrow vs peripheral blood stem cells), and the disease risk category. The randomisation was open label; all investigators 
were aware of the treatment allocation. The primary endpoint of the study was 100-day cumulative incidence of 
grade II–IV acute GVHD. Statistical analyses were done according to the per-protocol principle. Other outcomes included 
cumulative incidence of chronic GVHD, non-relapse mortality, disease recurrence, and probability of overall survival and 
event-free survival. This study was registered with ClinicalTrials.gov, number NCT00934557.
Findings Between Jan 15, 2008, and Sept 25, 2012, 89 patients were randomly assigned to the 30 mg/kg ATLG group 
and 91 to the 15 mg/kg ATLG group; 84 patients in the 30 mg/kg ATLG group and 88 in the 15 mg/kg ATLG group 
were included in the analysis. The median follow-up for the whole study population was 3·4 years (IQR 1·7–5·1). The 
100-day cumulative incidence of grade II–IV acute GVHD was 36% (95% CI 28–48) in the 15 mg/kg ATLG group 
and 29% (20–40) in the 30 mg/kg ATLG group (hazard ratio [HR] 0·74, 95% CI 0·44–1·25; p=0·26). The cumulative 
incidence of non-relapse mortality was 9% (5–18) in the 15 mg/kg ATLG group and 19% (12–30) in the 30 mg/kg 
ATLG group (HR 2·08, 0·89–4·96; p=0·092). Cumulative incidence of disease recurrence was 15% (12–24): 14% 
(8–23) in the 15 mg/kg ATLG group versus 20% (13–31) in the 30 mg/kg ATLG group (HR 1·54, 0·74–3·21; p=0·25). 
The 5-year overall survival probability was 70% (62–77) for the whole study population: 78% (69–87) in the 15 mg/kg 
ATLG group versus 62% (50–73) in the 30 mg/kg ATLG group (HR 1·80, 1·01–3·20; p=0·045). The 5-year event-free 
survival was 77% for children in the 15 mg/kg ATLG group versus 61% in the 30 mg/kg ATLG group (HR 1·87, 
1·07–3·28; p=0·028). 
Interpretation Children with haematological malignancies transplanted from unrelated donors selected through 
high-resolution HLA-typing benefit from the use of a 15 mg/kg ATLG dose in comparison with a 30 mg/kg ATLG 
dose. ATLG at 15 mg/kg should thus be regarded as the standard serotherapy regimen for unrelated donor allogeneic 
HSCT in this patient population. Future randomised studies will continue to aim to optimise patient outcome and 
strategies to prevent acute GVHD occurrence.
Funding Fresenius/Neovii Biotech.
Introduction
Acute and chronic graft-versus-host disease (GVHD) 
remain major complications of allogeneic haemopoietic 
stem-cell transplantation (HSCT). GVHD is associated 
with an increased risk of non-relapse mortality and a 
reduction in quality of life.1–3 Anti-T-lymphocyte globulin 
(ATLG) has been widely used for prevention of acute and 
chronic GVHD in patients given allogeneic HSCT. In the 
past few years, different groups have shown in 
randomised clinical trials that the addition of ATLG to 
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GVHD prophylaxis decreases the risk of both acute and 
chronic GVHD in adults receiving either HSCT from an 
unrelated donor4–7 or peripheral blood stem-cell 
transplantation from an HLA-identical sibling.8 However, 
recent findings have suggested that treatment with ATLG 
could increase the risk of relapse and infections, 
potentially hampering the benefits of improved GVHD 
prevention.9 In fact, ATLG administration has been 
shown to be associated with delayed T-cell reconstitution, 
including that of naive and memory T lymphocytes, and 
with an increased risk of infectious complications and 
post-transplant lymphoproliferative disease.10–12
Rabbit ATLG is the preferred agent for approaches 
of GVHD prevention through serotherapy in HSCT. 
However, two diverse rabbit ATLG preparations are 
available for clinical use in patients given allogeneic 
HSCT, which can have different effects on outcome and 
markedly different efficacies because their different 
preparation methods cause them to differ substantially 
in potency and dosing.13
None of the previously published trials has focused on 
a paediatric population. We hypothesised that fine 
tuning of GVHD prophylaxis and, particularly, of the 
dose of ATLG administered before allogeneic unrelated 
donor HSCT, could have an important role in the 
outcome of paediatric patients. To try to define the 
better dose of rabbit ATLG, we did a prospective, 
multicentre, clinical trial comparing two different doses 
of the drug (15 mg/kg vs 30 mg/kg) in children affected 
by haematological malignancies transplanted with 
either bone marrow or peripheral blood stem cells from 
an unrelated donor selected using high-resolution 
molecular typing for class I and II HLA loci. We chose 
to compare 30 mg/kg versus 15 mg/kg of ATLG instead 
of the dose of 60 mg/kg used in unrelated donor HSCT 
recipients in the trial published by Finke and colleagues6 
because children are less prone to developing GVHD 
compared to adults.3,14 This choice is supported by a 
retrospective analysis showing that 30 mg/kg of ATLG 
in a single dose was as effective for the prevention of 
GVHD as 60 mg/kg administered over 3 days in adults 
with haematological malignancies given HSCT from an 
unrelated volunteer.15 In that trial, the 2-year non-relapse 
mortality was lower for the ATLG 30 mg/kg group than 
Research in context
Evidence before this study
This study was designed in 2007 with the aim of identifying 
the recommended dose of rabbit anti-T-lymphocyte globulin 
(ATLG) for prevention of acute graft-versus-host disease 
(GVHD) in children with haematological malignancies given 
allogeneic haemopoietic stem-cell transplantation (HSCT) 
from an unrelated donor. At that time, a previously published 
randomised trial in adult recipients of HSCT had shown that, 
in comparison with patients given placebo, patients treated 
with high-dose ATLG had a lower incidence and severity of 
GVHD, at the price of a greater risk of infection-related 
mortality. A second randomised trial of ATLG in adults given 
allogeneic HSCT from an unrelated donor was published in 
2009, with a follow-up report in 2011. This second study 
confirmed that patients given ATLG (60 mg/kg) benefited 
from lower incidence and severity of acute GVHD, but also 
found a decrease in the incidence of chronic GVHD in 
comparison with patients receiving the placebo. A third 
randomised trial published in 2016 in adults given unrelated 
donor HSCT and comparing rabbit ATLG versus placebo 
provided support to previous findings, reporting that ATLG 
prophylaxis of GVHD decreased the number of patients 
needing immunosuppressive treatment at 1 year after 
transplantation.
However, none of the three studies focused on paediatric 
patients or addressed the issue of the dose of ATLG needed to 
prevent GVHD occurrence while preserving recovery of 
pathogen-specific immunity.
We updated this information by searching MEDLINE for 
articles published in any language between Jan 1, 2008, and 
Jan 1, 2017, using the search terms “hematopoietic stem cell 
transplantation” OR “bone marrow transplantation” OR “stem 
cell transplantation” OR “peripheral blood stem cell 
transplantation” AND “antithymocyte globulin” OR 
“anti-T-lymphocyte globulin” OR “GvHD prophylaxis in 
children”, but identified no additional prospective randomised 
trials of ATLG done in children receiving unrelated donor 
transplantation
Added value of this study
To the best of our knowledge, this is the first randomised 
clinical trial comparing two different doses of ATLG in unrelated 
donor HSCT recipients ever done. Moreover, none of the 
previously mentioned studies have focused on paediatric 
patients, whereas our own prospective randomised trial 
included only children. We have a long follow-up (median value 
for surviving patients: 4·2 years, IQR 3·2–5·8), rendering our 
data reliable and robust enough to draw definitive conclusions. 
The results of our study show that children with haematological 
malignancies given an unrelated donor HSCT should receive 
low-dose (15 mg/kg) instead of high-dose (30 mg/kg) ATLG to 
avoid the increased risk of non-relapse mortality and 
subsequent decreased probability of event-free survival.
Implications of all the available evidence
The advantage of low-dose ATLG is further supported in the 
subset of children with acute lymphoblastic leukaemia, which 
represents the most frequent indication to HSCT in comparison 
with other childhood haematological malignancies. Notably, a 
reduction in the ATLG dose to 15 mg/kg did not affect the time 
to engraftment and, more importantly, the incidence of acute 
or chronic GVHD.
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the 60 mg/kg group (12% vs 33%, p=0·02), mainly 
because of a higher incidence of fatal infections in the 
60 mg/kg group.15
Methods
Study design and participants
This multicentre, randomised, open-label, phase 3 study, 
enrolling children with haematological malignancies 
given allogeneic HSCT from an unrelated donor, was 
done in seven Italian centres in collaboration with the 
HSCT Working Group of the Italian Association for 
Paediatric Haematology and Oncology (AIEOP) network 
(appendix p 15).
Inclusion criteria were: diagnosis of acute leukaemia 
in morphological complete remission, or, Philadelphia-
positive chronic myeloid leukaemia in chronic phase, 
non-Hodgkin lymphoma in complete remission, or 
myelodysplasia; aged 0–18 years at transplantation; a life 
expectancy of at least 2 months; the availability of an 
unrelated donor selected with high-resolution molecular 
typing of HLA-A, HLA-B, HLA-C, and DRB1 loci, with 
no more than two allelic disparities, or one antigenic 
difference; and use of bone marrow-derived stem cells 
or granulocyte-colony stimulating factor-mobilised 
peripheral blood stem cell. Patients must also have had 
acceptable cardiac, renal, liver, and pulmonary function 
to tolerate the transplantation procedure. Exclusion 
criteria were: previous allogeneic or autol ogous HSCT; 
use of cord blood as stem-cell source; treatment with 
rabbit ATLG in the 3 months before transplantation (no 
previous treatment with any other drug represented an 
exclusion criterion); previous history of allergic 
reactions to ATLG; or absence of signed informed 
consent.
The institutional review board or ethical committee of 
each participating centre approved the study. Written, 
informed consent was obtained from patients’ parents or 
their legal guardians before enrolment. The study 
protocol is available in the appendix (pp 16–29).
Randomisation
To avoid imbalance between the two groups, before 
randomisation, patients were stratified according to the 
degree of compatibility with their donor (zero or one 
allelic disparity vs two allelic disparities or one antigenic 
disparity at the HLA loci), the source of haemopoietic 
stem cells used (bone marrow vs peripheral blood stem 
cells), and the disease risk category (standard risk vs high 
risk). Details on the stratification criteria are reported in 
the appendix (p 2). Patients were then randomly 
assigned (1:1) to receive ATLG at a total dose of either 
30 mg/kg or 15 mg/kg.
Randomisation was done through a remote AIEOP 
data entry system; the personnel of the trial units and 
the individual investigators did not have access to 
any randomisation listings. The randomisation code was 
generated by nQuery Advisor (version 5.0), with the use 
See Online for appendix
ATLG 
15 mg/kg 
(n=88)
ATLG 
30 mg/kg 
(n=84)
Sex
Male 54 (61%) 54 (64%)
Female 34 (39%) 30 (36%)
Age at diagnosis (years) 7·5 (1–18) 7·0 (1–18)
Diagnosis
ALL 50 (57%) 44 (52%)
AML 21 (24%) 21 (25%)
CML 1 (1%) 2 (2%)
MDS 12 (14%) 13 (15%)
NHL 4 (5%) 4 (5%)
Age at HSCT (years) 9·0 (1–19) 9·0 (1–19)
Disease risk category
Standard risk 57 (65%) 50 (60%)
High risk 31 (35%) 34 (40%)
Year of transplantation
2008 12 (14%) 8 (10%)
2009 13 (15%) 18 (21%)
2010 16 (18%) 15 (18%)
2011 26 (30%) 24 (29%)
2012 21 (24%) 19 (23%)
Donor–recipient HLA disparity
Identical 49 (56%) 44 (52%)
1 difference 29 (33%) 34 (40%)
2 differences 10 (11%) 6 (7%)
Identical or 1 allele disparity 64 (73%) 61 (73%)
1 antigen or >1 allele disparity 24 (27%) 23 (27%)
Stem-cell source
Bone marrow 72 (82%) 70 (83%)
Peripheral blood 16 (18%) 14 (17%)
Conditioning regimen
Busulfan-based 30 (34%) 38 (45%)
Busulfan + cyclophosphamide 
+ melphalan
18 (60%) 25 (66%)
Busulfan + thiotepa 
+ cyclophosphamide
7 (23%) 8 (21%)
Busulfan + cyclophosphamide 5 (17%) 5 (13%)
Treosulfan-based 13 (15%) 13 (15%)
Thiotepa + treosulfan + fludarabine 7 (54%) 9 (69%)
Treosulfan + fludarabine 6 (46%) 4 (31%)
TBI-based 45 (51%) 33 (39%)
TBI + thiotepa + cyclophosphamide 29 (64%) 20 (61%)
TBI + thiotepa + fludarabine 11 (24%) 7 (21%)
TBI + etoposide 5 (11%) 6 (18%)
Cell dose infused
Bone marrow (TNC × 10⁸/kg) 4 (2–7) 5 (2–9)
Peripheral blood (CD34+ cell × 10⁶/kg) 7 (3–8) 6 (3–8)
Data are n (%) or median (IQR). ATLG=anti-T-lymphocyte globulin. ALL=acute 
lymphoblastic leukaemia. AML=acute myeloid leukaemia. CML=chronic myeloid 
leukaemia. MDS=myelodysplastic syndrome. NHL=non-Hodgkin lymphoma. 
HSCT=haemopoietic stem-cell transplantation. TBI=total body irradiation. 
TNC=total nucleated cells.
Table 1: Patient and transplant characteristics
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of a block randomisation plan and a block size of four. 
The randomisation was open label; all investigators were 
aware of the treatment allocation.
Procedures
All patients were given a myeloablative regimen, chosen 
according to the disease and the policy of each 
participating centre (see table 1 for further details on the 
conditioning regimens used).
GVHD prophylaxis consisted of the combination of 
cyclosporine-A, administered intravenously at an initial 
dose of 3 mg/kg per day in two divided doses, starting 
from day –7, until the drug could be administered orally 
at a dose of 6 mg/kg per day in two divided doses, and 
short-term methotrexate (15 mg/m² on day 1 and 
10 mg/m² on days 3, 6, and 11 after transplantation). 
Rabbit ATLG (Grafalon; provided by Fresenius/Neovii) 
was given as intravenous infusion on days –4, –3, and –2 
at a dose of either 10 mg/kg per day (total dose of 
30 mg/kg) or 5 mg/kg per day (total dose of 15 mg/kg). 
Patients who had leukaemia relapse after randomisation 
were not excluded from the study (ie, they were followed 
up) but were not included in the per-protocol analysis. 
Dose modification of ATLG and interruption of the drug 
administration were not permitted, and would lead to 
patient removal from the study.
Tests for blood cell count and liver and kidney function 
were taken at least every other day until the patient was 
discharged. The same laboratory monitoring was 
repeated at least twice per week until day 100 after 
transplantation and then every month until 1 year after 
the allograft. We assessed adverse events continuously 
throughout the treatment period.
We diagnosed and staged haematological malignancies 
both before and regularly after HSCT on an ad-hoc basis 
using standard techniques of bone marrow aspiration, 
bone marrow biopsy, flow cytometry, histological stains, 
karyotyping, and molecular probes, as needed, following 
well established international diagnostic and staging 
recommendations for each malignancy. In particular, the 
state of remission of patients’ neoplastic disease was 
assessed at 3, 6, 9, and 12 months after transplantation.
Recipients at risk of infection with human 
cytomegalovirus (ie, children either positive for cyto-
megalovirus antibodies or negative but transplanted 
from a seropositive donor) were regularly monitored 
for infection by quantitative PCR on blood samples. 
Recommendations for management of adenovirus and 
Epstein-Barr virus infection included regular screening 
of all enrolled participants by quantitative PCR on blood 
samples.
Outcomes
The primary endpoint of the study was 100-day cumulative 
incidence of grade II–IV acute GVHD in the two 
randomisation groups. Secondary endpoints included 
cumulative incidence of chronic GVHD, disease 
recurrence, non-relapse mortality (defined as the 
probability of death from time of HSCT from any cause 
other than disease recurrence or progression), viral 
reactivations (Epstein-Barr virus, cytomegalovirus, and 
adenovirus), post-transplantation lymphoproliferative 
disorders, fungal infections in the two groups, and overall 
survival. Neutrophil and platelet engraftment (time from 
HSCT to the first of 3 consecutive days with an absolute 
neutrophil count greater than or equal to 0·5 × 10⁹/L, and 
time from HSCT to the first of 7 consecutive days with an 
unsupported platelet count greater than or equal to 
50 × 10⁹/L, respectively), the probability of event-free 
survival (defined as the probability of survival without 
evidence of disease at any time after transplant; death, 
relapse and rejection with or without autologous 
hematopoietic reconstitution were considered events, 
while patients who were alive, who had sustained donor 
engraftment and were disease-free were censored at last 
follow-up), and the composite endpoint of chronic GVHD-
free and relapse-free survival were assessed post hoc.16 
Safety assessments included reports of adverse events 
graded according to Common Terminology Criteria 4.02 
and incidences of serious infection including reactivation 
of Epstein-Barr virus, cytomegalovirus, or adenovirus.
Figure 1: Trial profile
ATLG=anti-T-lymphocyte globulin.
91 assigned to the ATLG 15 mg/kg group
3 did not receive transplant
 3 had further pretransplant
     relapse
88 transplanted with ATLG 15 mg/kg
20 events
 12 relapses
 8 deaths in remission
68 alive and disease free
88 analysed
89 assigned to the ATLG 30 mg/kg group
5 did not receive transplant
 5 had further pretransplant
     relapse
84 transplanted with ATLG 30 mg/kg
32 events
 16 relapses
 16 deaths in remission
52 alive and disease free
84 analysed
187 patients assessed for eligibility
7 ineligible
 7 did not meet inclusion criteria
180 enrolled
180 randomly assigned
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Statistical analysis
We calculated the sample size on the basis of an expected 
100-day rate of grade II–IV acute GVHD of 25% in the 
30 mg/kg ATLG group and of 50% in the 15 mg/kg ATLG 
group. We estimated a sample size of 160 patients 
(80 patients in each group) considering a power of 0·80 
and α equal to 0·05 to reject the null hypothesis in a log-
rank test model. The detailed trial protocol is provided in 
the appendix (pp 16–29).
Data on patients randomly assigned in the study were 
collected in the data warehouse of the AIEOP HSCT 
group. Both primary and secondary endpoints were 
assessed by the two statisticians of the group (CR and 
MZ). Data were analysed as of March 1, 2016. All 
statistical analyses were done according to the per-
protocol principle.
Acute and chronic GVHD, rejection, engraftment, 
overall survival, event-free survival, non-relapse mortality, 
and relapse incidence were estimated from the date of 
transplantation to the date of an event or last follow-up. 
Probabilities of overall survival and event-free survival 
were calculated according to the Kaplan-Meier method. 
We calculated acute GVHD, chronic GVHD, non-relapse 
mortality, and relapse as cumulative incidence curves to 
adjust the estimates for competing risks. All results were 
expressed as probability or cumulative incidence and 
95% CI.17,18 All transplanted patients were assessed for 
acute GVHD occurrence (assessed at day 100 after 
transplantation), whereas patients surviving more than 
100 days were assessed for chronic GVHD. We assessed 
severity of acute GVHD according to the Glucksberg 
criteria and chronic GVHD according to the modified 
Seattle criteria (for categorisation of chronic GVHD as 
clinically limited or extensive).19,20 When we estimated 
GVHD occurrence, we regarded both rejection and non-
relapse mortality as competing events.21
We estimated the significance of differences between 
event-free survival and overall survival with the log-rank 
test (Mantel-Cox), and used Gray’s test to assess, in 
univariable analyses, differences between cumulative 
incidences.22 The following variables were investigated 
for their effect on cumulative incidence of grade II–IV 
acute GVHD and event-free survival: patient sex, patient 
age, diagnosis, risk stratification, HLA-disparity, stem-
cell source, cytomegalovirus serology in the donor–
recipient pair, use of total body irradiation during the 
conditioning regimen, and dose of ATLG. Effect of 
chronic GVHD on event-free survival was also 
investigated. Multivariable analysis was done using the 
Cox proportional hazard regression model.17,18 All 
variables found to be significant in the univariable 
analysis and the variables used for patient stratification 
were included in the multivariable model. Analyses were 
done in the per-protocol population. Other details on 
statistical analysis are shown in the appendix (p 2).
Statistical analysis was performed using NCSS 10 and 
R 2.5.0 software package.23,24
This study was registered with ClinicalTrials.gov, 
number NCT00934557.
Role of the funding source
Neovii Biotech, which provided the ATLG (Grafalon), had 
no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. FL, MEB, 
and MZ had full access to all the data in the study and all 
the authors made the decision to submit the manuscript 
for publication.
Results
Between Jan 15, 2008, and Sept 25, 2012, 187 patients 
were screened for inclusion in the present study. Seven 
patients were excluded from randomisation because they 
did not fulfil all the inclusion criteria. 180 patients were 
enrolled and randomly assigned: 89 were assigned to the 
30 mg/kg ATLG group and 91 to the 15 mg/kg ATLG 
group (figure 1). Eight patients, five in the 30 mg/kg 
ATLG group and three in the 15 mg/kg ATLG group, did 
not proceed to transplantation due to relapse before 
HSCT and were subsequently excluded from the analysis. 
The remaining 172 patients (84 in the ATLG 30 mg/kg 
group and 88 in the 15 mg/kg group), underwent HSCT 
and were included in this analysis. No patient required 
dose reduction or discontinued the planned treatment 
for any reason, including drug-related toxicity.
The two randomisation groups were similar for all 
demographic and transplant-related variables assessed 
(table 1).
The median follow-up was 3·4 years (IQR 1·7–5·1) for 
the whole study population, 4·2 years (IQR 3·2–5·8) 
for patients alive at last follow-up, and 0·7 years 
(IQR 0·2–1·0) for those who died. For those patients who 
survived, the median follow-up was 4·2 years 
(IQR 3·4–6·0) for the 30 mg/kg group and 4·1 years 
(IQR 3·1–5·7) for the 15 mg/kg group.
Two patients (one per group) did not engraft. The 
median time to neutrophil engraftment in the whole 
study population was 20 days (IQR 16–23), with no 
difference in the two groups (data not shown). The median 
time to platelet engraftment was 24 days (IQR 19–31): 
26 days (IQR 20–35) in the 30 mg/kg ATLG group and 
22 days (IQR 18–29) in the 15 mg/kg ATLG group.
Among 172 patients in study (88 in the 15 mg/kg 
ATLG group vs 84 in the 30 mg/kg ATLG group), 
40 (23%) developed grade I acute GVHD (22 [25%] vs 
18 [21%]), 44 (26%) grade II (27 [31%] vs 17 [20%]), 
six (3%) grade III (four [5%] vs two [2%]), and six (3%) 
grade IV (one [1%] vs five [6%]), whereas 76 (44%) did 
not present any grade of acute GVHD (34 [39%] vs 
42 [50%]; figure 2, appendix p 3). No difference was seen 
between the two groups. The overall 100-day cumulative 
incidence of grade II–IV acute GVHD for all patients 
was 33% (95% CI 26–40), whereas that of grade III–IV 
acute GVHD was 7% (95% CI 4–12). The cumulative 
incidence of grade II–IV and of grade III–IV acute 
For NCSS 10 statistical 
software see ncss.com/
software/ncss
For R 2.5.0 software package 
see http://www.R-project.org
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GVHD was similar between the two groups (figure 2, 
appendix p 3). Analysis of the variables affecting 
occurrence of grade II–IV acute GVHD is shown in 
appendix (pp 4–5). Post-hoc analyses showed that 
patients transplanted from a donor who was not fully 
HLA-compatible had a greater risk of developing 
grade II–IV acute GVHD. Grade I (ie, skin-only) acute 
GVHD was homogeneously treated with topical steroids 
or low-dose (ie, less than 1 mg/kg) systemic steroids. 
Grade II–IV acute GVHD was initially treated with 
steroids; patients who did not respond to steroids were 
given various different second-line therapies.
156 patients (83 in the 15 mg/kg ATLG group and 73 in 
the 30 mg/kg ATLG group) surviving more than 100 days 
after HSCT were assessed for chronic GVHD occurrence. 
Chronic GVHD was absent in 124 (79%) patients 
(65 [78%] vs 59 [81%]), clinically limited in 20 (13%; 
ten [12%] vs ten [14%]), and clinically extensive in 12 (8%; 
eight [10%] vs four [5%]). The overall cumulative 
incidence of chronic GVHD (limited plus extensive) 
was 21% (95% CI 15–28), with no difference seen 
between the two groups (figure 2, appendix p 3).
The overall cumulative incidence of extensive chronic 
GVHD alone was 8% (95% CI 4–14): 6% (2–14) for the 
30 mg/kg ATLG patients and 10% (5–19) for the 15 mg/kg 
ATLG group (hazard ratio [HR] 0·56, 95% CI 0·17–1·83; 
p=0·33; figure 2).
23 (13%) of 172 patients died in remission due to 
transplant-related causes: 15 (18%) of 84 patients in the 
30 mg/kg ATLG group and eight (9%) in the 15 mg/kg 
ATLG group. The overall cumulative incidence of non-
relapse mortality was 14% (95% CI 9–21; figure 3). 
Different causes of death in the two groups are detailed 
in the appendix (p 6). Notably, more infection-related 
deaths occurred in the 30 mg/kg ATLG group (seven) 
than in the 15 mg/kg ATLG group (three).
Appendix (p 7) shows the cumulative incidence of viral 
infections (human cytomegalovirus, Epstein-Barr virus, 
Figure 2: Cumulative incidence of GVHD
(A) Grade II–IV acute GVHD. (B) Grade III–IV acute GVHD. (C) Chronic GVHD. (D) Extensive chronic GVHD. HR=hazard ratio. HSCT=haemopoietic stem-cell 
transplantation. GVHD=graft-versus-host disease. ATLG=anti-T-lymphocyte globulin. E=events.
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30 mg/kg n=73; E=4; 6% (95% CI 2–14)
HR 0·56 (95% CI 0·17–1·83); p=0·33
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and adenovirus reactivation and disease) and of invasive 
aspergillosis in the whole study population and in the 
two groups. Notably, patients receiving the 30 mg/kg 
ATLG dose had a greater cumulative incidence of viral 
reactivations than children who received the 15 mg/kg 
dose. The difference was significant for Epstein-Barr 
virus reactivation (31 [37%, 95% CI 28–49] of 84 vs 
20 [23%, 15–33] of 88; p=0·038) and for adenovirus 
reactivation (ten [12%, 7–21] of 84 vs one [1%, 0–8] of 88; 
p=0·02). Two patients given 30 mg/kg dose ATLG in our 
study developed post-transplantation lympho proliferative 
disorders and one died from this complication. 
Additionally, the incidence of human cytomegalovirus 
reactivation (32 [38%, 29–50] of 84 vs 28 [32%, 23–43] of 88; 
p=0·48) and invasive aspergillosis (five [6%, 3–18] of 84 vs 
two [2%, 1–9] of 88; p=0·26) were slightly, but non-
significantly, higher in the 30 mg/kg ATLG group than in 
the 15 mg/kg ATLG group.
29 (17%) of 172 patients relapsed at a median of 
6·6 months after HSCT (range 1·9–21·8; IQR 4·1–15·3), 
the cumulative incidence of relapse being 15% (95% CI 
12–24). 17 relapses occurred in the 30 mg/kg ATLG group 
and 12 in the 15 mg/kg ATLG group (figure 3). The 
cumulative incidence of relapse was not statistically 
affected by the occurrence of chronic GVHD (appendix 
p 2). No patient received prophylactic donor lymphocyte 
infusions for prevention of leukaemia recurrence. 
Relapsing patients were treated with several therapies, 
none of which showed greater benefit in comparison 
with the others (data not shown).
123 (72%) patients were alive at time of the last follow-
up (69 in the 15 mg/kg ATLG group vs 54 in the 30 mg/kg 
ATLG group): 120 (68 vs 52) were in continuous complete 
remission after HSCT, and three (one vs two) were alive 
after a post-transplantation leukaemia relapse. At time of 
writing, no patient has developed a secondary 
malignancy.
The 5-year overall survival probability was 70% (95% CI 
62–77) for the whole study population: 62% (50–73) for 
the patients in the 30 mg/kg ATLG group and 78% 
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Figure 3: 5-year overall survival, event-free survival, and cumulative incidence of relapse and non-relapse mortality
(A) Overall survival, event-free survival, and cumulative incidence of relapse and non-relapse mortality for the whole population. Event-free survival (B) and 
cumulative incidence of non-relapse mortality (C) and relapse (D) by randomisation group. OS=overall survival. EFS=event-free survival. REL=relapse. NRM=non-
relapse mortality. E=events. HR=hazard ratio. HSCT=haemopoietic stem-cell transplantation. ATLG=anti-T-lymphocyte globulin. 
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(69–87) for patients in the 15 mg/kg ATLG group 
(HR 1·80, 95% CI 1·01–3·20; p=0·045).
Overall, the 5-year event-free survival of the whole 
cohort was 69% (95% CI 62–76): 61% (50–72) for the 
patients in the 30 mg/kg ATLG group and 77% (68–85) 
for patients in the 15 mg/kg ATLG group (HR 1·87, 
95% CI 1·07–3·28; p=0·028; figure 3). Analysis of other 
variables potentially affecting event-free survival is 
shown in appendix (p 8–9). The results of the post-hoc 
survival analysis for specific subgroups of patients, 
including patients with acute leukaemia and subsets of 
patients stratified according to disease risk category, 
degree of donor–recipient HLA compatibility, and source 
of stem cells, are summarised in the appendix (pp 10–12). 
Event-free survival and overall survival was better in 
patients who received a 15 mg/kg dose of ATLG (appendix 
p 14) and a transplant from a donor who was not fully 
HLA-compatible than in patients who received 30 mg/kg 
doses of ATLG. Children with standard-risk disease had a 
better event-free survival probability than high-risk 
patients (appendix p 10), and patients transplanted from 
a donor who was HLA-identical or one allelic disparate 
had better outcomes than patients transplanted from a 
donor showing a greater disparity with the recipient, 
although the difference in the univariable analysis was 
not significant (appendix p 12). Notably, in many other 
post-hoc subgroup analyses, we saw an advantage in 
terms of event-free survival for patients who received 
ATLG at the 15 mg/kg dose versus patients who received 
the 30 mg/kg dose (appendix pp 10–11). This advantage 
was significant for all patients with acute leukaemia 
(p=0·049) and for patients affected by acute lymphoblastic 
leukaemia (p=0·049). We also assessed chronic GVHD-
free plus relapse-free survival, and extensive chronic 
GVHD-free plus relapse-free survival (appendix p 3, 13). 
There were no significantly better differences between 
the two groups.
Table 2 summarises the results of multivariable 
analysis of grade II–IV acute GVHD, event-free survival, 
non-relapse mortality, and relapse. In the multivariable 
analysis of event-free survival, the following variables 
were associated with worse outcome: ATLG dose of 
30 mg/kg, HLA disparity of more than one allele, and 
high-risk disease. Only the high-risk disease group was 
significantly associated with an increased risk of relapse, 
whereas the ATLG dose of 30 mg/kg was associated with 
an increased risk of non-relapse mortality.
Discussion
Our results show that, in an era in which high-resolution 
molecular typing for class I and class II HLA loci has 
significantly improved the clinical outcome of unrelated 
donor-HSCT by decreasing the risk of immunological 
complications,14,25 lowering the ATLG dose to 15 mg/kg 
did not affect the time to engraftment and, more 
importantly, the incidence of acute or chronic GVHD, 
and was associated with an improved probability of 
Relative risk (95% CI) p value
Grade II–IV acute graft-versus-host disease
Disease risk category
High risk vs standard risk 0·59 (0·32–1·08) 0·087
HLA compatibility
>1 allele mismatch vs identical or 
1 allele mismatch
2·22 (1·29–3·85) 0·0043
Stem-cell source
Peripheral blood vs bone marrow 0·76 (0·36–1·61) 0·470
Donor→recipient cytomegalovirus serology
Negative→positive vs 
negative→negative
11·52 (1·57–84·47) 0·016
Positive→negative vs 
negative→negative
7·42 (0·98–56·69) 0·053
Positive→positive vs 
negative→negative
10·34 (1·43–74·78) 0·021
Randomisation group
ATLG dose: 30 mg/kg vs 
15 mg/kg
0·76 (0·42–1·38) 0·370
Event-free survival
Disease risk category
High risk vs standard risk 2·46 (1·41–4·27) 0·0015
HLA compatibility
>1 allele mismatch vs identical or 
1 allele mismatch
2·08 (1·2–3·7) 0·0111
Stem-cell source
Peripheral blood vs bone marrow 0·92 (0·41–2·07) 0·885
Randomisation group
ATLG dose: 30 mg/kg vs 
15 mg/kg
1·90 (1·07–3·3) 0·0256
Non-relapse mortality
Disease risk category
High risk vs standard risk 1·56 (0·68–3·54) 0·187
HLA compatibility
>1 allele mismatch vs identical 
or 1 allele mismatch
2·00 (0·87–4·59) 0·107
Stem-cell source
Peripheral blood vs bone marrow 0·25 (0·03–1·88) 0·473
Randomisation group
ATLG dose: 30 mg/kg vs 
15 mg/kg
1·80 (1·07–3·0) 0·047
Relapse
Disease risk category
High risk vs standard risk 3·52 (1·65–7·51) 0·0012
HLA compatibility
>1 allele mismatch vs identical or 
1 allele mismatch
2·12 (0·94–4·58) 0·0551
Stem-cell source
Peripheral blood vs bone marrow 1·95 (0·81–4·67) 0·081
Randomisation group
ATLG dose: 30 mg/kg vs 
15 mg/kg
1·80 (0·85–3·81) 0·126
ATLG=anti-T-lymphocyte globulin.
Table 2: Multivariable analysis on grade II–IV acute graft-versus-host 
disease, event-free survival, non-relapse mortality, and relapse risk
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event-free survival, mainly due to a reduced risk of non-
relapse mortality.
Although in-vivo serotherapy has been mainly used in 
the past two decades to reduce the incidence and severity 
of GVHD, few randomised trials have been done4–9 and, 
to the best of our knowledge, none of these in paediatric 
patients. Moreover, all of these controlled trials compared 
either rabbit-antihuman T-cell line (Jurkat) globulin 
(Grafalon, Neovii Biotech) versus no ATLG6,8,9 or rabbit-
antihuman thymocyte globulin (Thymoglobulin, 
Genzyme) versus no ATLG,4,5,7 but no randomised study 
has addressed the issue of drug dose. As such, the 
optimum ATLG therapeutic window and the timing of 
treatment have not yet been defined. We report the 
results of the first randomised clinical trial designed to 
establish the better of two doses of rabbit ATLG for the 
prevention of acute GVHD, while maintaining the 
capacity of effectively controlling or eradicating infections 
and leukaemia regrowth in children undergoing 
transplantation with either bone marrow-derived or 
peripheral blood stem cell-derived grafts from an 
unrelated donor.
Limitations of our study include supportive care 
continually changing over the course of the trial, the 
heterogeneity of disease treated with transplantation 
(including chronic myelogenous leukaemia, which is 
rarely treated with an allograft nowadays) and of 
conditioning regimens used, and the scarcity of data on 
immune reconstitution, particularly on pathogen-specific 
immunity. Despite these limitations and the choice of 
administering ATLG in an open-label manner, we found 
that children given 30 mg/kg ATLG had a higher 
incidence of infection-related deaths than children given 
the 15 mg/kg dose (seven deaths vs three); moreover, the 
children given 30 mg/kg ATLG also had an increased 
risk of adenovirus and Epstein-Barr virus infections. 
Although we do not have data on virus-specific immune 
reconstitution in the two groups, several studies11,26 have 
reported that ATLG has a half-life of 7–14 days, which 
means that patients are exposed to ATLG both before and 
after HSCT, and substantial evidence exists that higher 
doses of ATLG are associated with slower recovery of 
pathogen-specific immunity and higher incidence of 
fatal infections.4,9,10,12 Among patients undergoing HSCT, 
adenovirus infections have a much higher prevalence in 
paediatric patients (20–26%) than in adults (9%), possibly 
because of the reservoir of adenovirus in the general 
paediatric population.27,28 The high doses of ATLG 
depleting antiviral T cells transferred with the graft due 
to the long half-life of the polyclonal antibodies could 
have a detrimental effect on recovery of pathogen-specific 
T-cell immunity, which was shown to be crucial for 
clearing the viral infection and preventing dissemination 
of adenovirus infection.27 Previous reports have also 
documented that both T-cell depletion and high rabbit 
ATLG serum concentrations on day 7 after HSCT are 
associated with increased risk of Epstein-Barr virus 
infection and post-transplantation lymphoproliferative 
disorders.29,30 Among children given 30 mg/kg ATLG in 
our study, one child of the two developing post-
transplantation lymphoproliferative disorders died from 
this complication. Notably, a study31 published in 2017 
showed that detection of multiple double-stranded DNA 
viruses has a dose-dependent association with increased 
mortality after HSCT.31
The use of 15 mg/kg ATLG was associated with 
statistically improved event-free survival in the subgroups 
of children with acute leukaemia or with acute 
lymphoblastic leukaemia, which represents the more 
frequent indication for an allograft in haematological 
malignancies of childhood. The 78% probability of event-
free survival at 5 years reported in the 50 children with 
acute lymphoblastic leukaemia given 15 mg/kg ATLG 
compares favourably to the results reported by Peters and 
colleagues25 in 306 children transplanted from an 
unrelated donor with a standardised transplantation and 
GVHD prophylaxis protocol (71% at 4 years).
Remarkably, the advantage of 15 mg/kg ATLG over the 
30 mg/kg dose was evident in patients transplanted 
from donors with one or more HLA-disparities, who 
represented almost half of the study population. This 
advantage was also found in patients given peripheral 
blood stem cells, a stem-cell source that, in comparison 
with bone marrow, was shown to be associated with 
more chronic GVHD in a randomised trial32 done in 
unrelated donor-HSCT recipients, probably reflecting 
the protective effect of intensive GVHD prophylaxis with 
cyclosporine, methotrexate, and rabbit ATLG.
In our cohort, the most frequent cause of treatment 
failure after transplantation was disease recurrence, 
which occurred in the first or, more rarely, second year 
after transplantation. The probability of relapse was 
not statistically affected by the dose of ATLG given, but 
instead mainly by the disease risk category, confirming 
that the stratification criterion chosen had a high 
predictive value on final outcome. Moreover, in our 
cohort, the 5-year overall survival probability was 70% 
and the event-free survival probability was 69%, 
indicating that once a child relapsed the chance of their 
rescue was negligible.
In this study, the composite endpoint of survival free 
from both chronic GVHD and relapse was similar 
between children given either 30 mg/kg or 15 mg/kg 
ATLG, suggesting that a lower dose of serotherapy does 
not affect the quality of life of surviving patients.
Different types of ATLG preparations have been tested 
as part of conditioning regimens to achieve in-vivo T-cell 
depletion or modulation and, thus, to prevent GVHD. 
The ATLG preparation used in our study is a polyclonal 
anti-human-T-lymphocyte immune globulin derived 
from rabbits after immunisation with the Jurkat human 
T-cell line. This product preferentially targets T cells; 
however, because other antigens such as CD19 or CD138 
are also targeted by ATLG,33 we cannot exclude a direct 
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antitumor effect of the drug in B-cell acute lymphoblastic 
leukaemia and to a lesser extent in myeloid leukaemias, 
particularly in the context of pretransplantation 
persisting minimal residual disease.
Pharmacokinetic analysis of ATLG was not done in 
our study. Notably, data reported in 2015 on pharmaco-
kinetics of ATLG in the paediatric population have 
shown that older children have a disproportionately 
higher exposure than younger children because they 
have a lower clearance of the drug per kilogram of body-
weight.10,11 Additionally, low lymphocyte count of the 
recipient at time of ATLG infusion was shown to 
translate into high exposure of donor T cells to the 
drug.10,11 These observations provide a rationale to 
envisage more sophisticated strategies in the future for 
the dose and timing of administration of ATLG on the 
basis of pharmacokinetics parameters.
In summary, our data obtained in a randomised clinical 
trial with a long follow-up indicate that, in children with 
haematological malignancies transplanted from an 
unrelated donor selected through high-resolution HLA 
typing, the use of 15 mg/kg rabbit ATLG results in better 
overall survival and event-free survival than a 30 mg/kg 
dose. 15 mg/kg ATLG can spare life-threatening viral 
infections without significantly increasing the incidence 
of acute and chronic GVHD, and without adversely 
affecting other outcomes such as engraftment or relapse.
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